Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06040684
Other study ID # INT-01-HLATX-Kidney
Secondary ID 15/RVO-FNOs/2018
Status Completed
Phase
First received
Last updated
Start date August 1, 2018
Est. completion date December 31, 2021

Study information

Verified date September 2023
Source University Hospital Ostrava
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Kidney transplantation is the best method of renal replacement in patients with irreversible renal failure. One of the biggest problems today is premature loss of function of the transplanted kidney. This occurs most often on the basis of chronic humoral rejection. This is the immune response to the kidney, in which the specific antibodies play a crucial role (both against the HLA and the non-HLA system). The aim of this study is to analyze one of the situations where the production of antibodies can begin to occur. This is a serious acute infection (bacterial, viral, or fungal), where it is necessary to significantly reduce doses of immunosuppressives. At the time of reduced immunosuppression, the immune system can recognize the transplanted kidney as foreign to the human body and begin to fight against it. In this study, the investigators will monitor antibodies against the transplanted kidney in patients with severe acute infection. A serious infection in this study is one that requires acute hospitalization and reduced doses of immunosuppressive drugs. The researchers will measure the antibodies in the blood upon admission and then in 5 weeks.


Description:

Kidney transplantation significantly improves the prognosis and quality of life of patients with irreversible renal failure (end-stage kidney disease), requiring hemodialysis or peritoneal dialysis. The length of the function of the transplanted kidney depends on a number of factors. One of the most significant deterioration factors and subsequent graft function failure, in the long run, is the production of antibodies against HLA as well as transplant antigens that lead to acute or chronic humoral rejection. Chronic humoral rejection leading to transplant glomerulopathy is the most common cause of loss of function of the transplanted kidney. Treatment interventions in this area are still ineffective. In spite of immunosuppressive therapy, some patients develop anti-transplant antibodies (both against HLA and non-HLA antibody molecules) even with stable graft function. However, these patients have an increased risk of losing their function due to chronic humoral rejection. The HLA-DR and HLA-DQ molecules have the greatest immunogenicity. Patients after kidney transplantation may have many complications. Both surgical (vascular anastomoses stenoses, wound healing problems, graft vascular thromboses, lymphocele, urinary leakage) and non-surgical, some of which are immune-compromised (rejection) and others, result from the mechanism of action of immunosuppressive preparations (infections, cardiovascular effects). Amongst potentially life-threatening conditions include acute infections. Immunosuppressed infections have their own specifics. In addition to the increased risk of infections; also a different spectrum of possible originators is known. It is also possible to encounter opportunistic infections - pneumocystis, cytomegalovirus, polyomavirus infections. Another specific feature is often a different course of infection - patients may not have significantly expressed clinical or laboratory findings and may progress rapidly. For these reasons, physicians are often forced to significantly reduce immunosuppression rates in patients with acute infection, despite the increased risk of developing rejection. This situation increases the risk of initiation by both cell-mediated rejection and antibody-mediated rejection. Signs of rejection are very nonspecific and the only diagnostic method is graft biopsy. Previous studies have shown that the production of antibodies to the transplanted kidney is preceded by clinical signs of deterioration in graft function over weeks to months. Patients included in the study according to the criteria will be examined for the presence of HLA antibodies and non-HLA on admission (within 48 hours of admission) and 5 weeks after the first sample method LUMINEX xMAP.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 31, 2021
Est. primary completion date November 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 years and over. - A kidney transplant patient - from a living donor or from a cadaveric donor (donor after circulatory or brain death). The patient will be included after 1st transplant and possible retransplantation. - The patient is hospitalized or newly admitted to the FN Ostrava internal clinic for acute infection + requires the reduction of immunosuppressive therapy (dose reduction or discontinuation of any of the maintenance immunosuppressive preparations - tacrolimus, cyclosporin A, sirolimus, everolimus, azathioprine, mycophenolate). - Acute infection (to be admitted to an internal clinic - determine the time of admission or the time of the first symptom of infection in the already hospitalized) occurred at least more than 48 hours after transplantation (from reperfusion time) and a maximum of 10 years after transplantation. - The patient did not receive intravenous immunoglobulins within the last 24 hours prior to first sampling. - This is not a pregnant woman. Exclusion Criteria: - Patient's death before the 2nd blood sampling. - The patient condition was conclusively determined as something other than acute infection (acute rejection episode, acute pancreatitis, malignant tumor, ...). Unfamiliarity with localization of the infection or its origin, assuming an infectious etiology, is NOT an exclusion criterion. - The patient was graftectomized - removal of the transplanted kidney, between the 1st and 2nd antibody determination. - Detection of pregnancy when the term of conception is calculated before the 2nd antibody count. - One or more transfusions of the erythrocytes or plasma between the 1st and 2nd measurements were administered to the patient.

Study Design


Intervention

Diagnostic Test:
Level of antibodies
The level of antibodies against transplanted kidney in patients with a severe acute infection will be measured upon admission and then in 5 weeks.

Locations

Country Name City State
Czechia University Hospital Ostrava Ostrava Moravian-Silesian Region

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Ostrava

Country where clinical trial is conducted

Czechia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Production of HLA and nonHLA antibodies - Luminex Screening for HLA and nonHLA antibodies by Luminex. The test result will be positive (MFI - mean fluorescence intensity above 300) or negative. 42 months
Secondary Analysis of antibody formation according to age The formation of antibodies will be analysed according to the age of the patients in years. 42 months
Secondary Analysis of antibody formation according to time from transplantation The formation of antibodies will be analysed according to the time from transplantation in months. 42 months
Secondary Creatinine value The baseline kidney function will be assessed (according to the KDIGO organization) The kidney will be classified as a normal function, 1st, 2nd, 3rd according to the creatinine value). 42 months
Secondary Input Inflammatory Parameters - CRP (C-reactive protein) The input inflammatory parameters will be assessed (CRP (mg/l). 42 months
Secondary Input Inflammatory Parameters - IL-6 (Interleukin-6) The input inflammatory parameters will be assessed (IL-6 (ng/l). 42 months
Secondary Number of HLA mismatches during transplant (0-6) The number of HLA mismatches during transplant (0-6) will be recorded. 42 months
Secondary Length of immunosuppression reduction The length of immunosuppression reduction will be analysed in 3 categories - up to 5 days, 5-10 days and over 10 days. 42 months
Secondary Delayed graft function after transplantation The delayed graft function after transplantation will be assessed in 2 categories - YES / NO -as a need for haemodialysis in the first week after transplantation. 42 months
Secondary Long-term graft function The long-term graft function will be assessed by the last early graft function (eGF) in ml / sec- 3 categories - normal function, G1-2 and G3-5 by KDIGO. 42 months
Secondary Type of infection The type of infection observed in the patients will be assessed and recorded - urinary, respiratory, other - determined by the doctor when the patient is discharged. 42 months
Secondary Presence of antibodies The presence of antibodies (YES/NO) will be determined in patients using the LUMINEX method - antibody value using MFI - mean fluorescence intensity. 42 months
Secondary EGF value The function of the transplanted kidney will be assessed at 6 months (+ -14 days) from the first measurement assessing the EGF value (ml/sec) 42 months
Secondary Proteinuria The function of the transplanted kidney will be assessed at 6 months (+ -14 days) from the first measurement assessing the proteinuria (g/l) 42 months
See also
  Status Clinical Trial Phase
Completed NCT04510090 - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus Phase 1
Completed NCT02546037 - Clotting With Different Dialyzer Membranes
Recruiting NCT02545920 - To Assess Ear Blood Flow During Dialysis
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Recruiting NCT01912001 - Virtual Ward for Home Dialysis N/A
Completed NCT00986947 - Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates Phase 2
Completed NCT01158742 - Live Kidney Donor Study -Renal Function Study N/A
Completed NCT00765661 - Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients Phase 2
Withdrawn NCT00807274 - Renal Function in Adults With Congenital Heart Disease. N/A
Completed NCT00369382 - Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients Phase 4
Completed NCT00183248 - Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients Phase 1/Phase 2
Enrolling by invitation NCT05324878 - Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
Completed NCT05272800 - BIS-guided Fluid Management in HD Patients N/A
Completed NCT03836508 - Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis N/A
Completed NCT01756508 - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury Phase 2
Completed NCT03723668 - Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
Recruiting NCT04277377 - Nanoparticle for DSA Removal
Terminated NCT00450333 - Dynepo Infrequent Dosing Study Phase 3
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Recruiting NCT04714853 - Different Dialysis Modalities and Diet on Gastrointestinal Biome and Azotaemic Toxins